INVENTIVA - (EGFF)

signed

Inventiva is a late-stage clinical-stage biopharmaceutical company. The promoter is a French biotechnology company with an in-depth expertise in small molecules targeting nuclear receptors, transcription factors and epigenetic enzymes. The company has built a strong pipeline of drug candidate for the treatment of patients with fibrosis, lysosomal storage disorders and cancers. The project supports the company's research and development (R&D) investments, including the clinical regulatory and manufacturing development costs of all portfolio candidates, with a focus on the lead products (e.g. Lanifibranor). Investments will cover predominantly R&D costs to bring the assets closer to the market authorisation and commercialisation.